CDX2 and breast cancer: MiR-9 expression was up-regulated in bladder transitional cell carcinoma, mixed lineage leukemia-rearranged acute myeloid leukemia, hepatocellular carcinoma, primary brain tumors, CDX2-negative gastric cancer cells and breast cancer [27–34].